Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is looking like another run is forthcoming. Get ready for it!
It's ok guys. This is just a small bump on the road back up to 1.50 and beyond. Way too much good information coming out and you can expect those investor conferences to get some major interest in here.
I am fired up - I know you longs are too. We will get there, don't worry!!
I can live with that assessment. But they had better be very sure on whether they sink the type of money into this because this will be a very expensive venture and it will take a few years to accomplish. Are they throwing good money after bad??
The FDA sent them a resounding 14-0 message - they were not satisfied at all and they need to go back to the drawing board. This will take a lot of time - and money.
14-0 is a pretty good knock out punch. NONE of them gave it the ok - they aren't even close.
At this point, why even bother going forward with it? It's a waste of time and a waste of money. Slow bleed to its painful death...
One more for you guys to watch --
Short SPPI as much as you can. The FDA came out with a vote of 14-0 against their drug Qapzola. They are in BIG trouble and their stock has not been taken down nearly enough. Probably take a huge further hit going forward. Check it out.
But take this to the bank!
The reason we won (or at least winning!) on this one is quite simple.
We dug out the facts and we got them before the herd got there. Others saw the information but didn't take the time to read or understand it or maybe they just didn't see the information at all. We hung in there even when the MM's blasted the price because we were confident with our information.
Going forward, there will continue to be some violent swings in either direction but I remain confident this will continue to climb over 1.00 to at least 1.50 near term. We have solid information and news - just continue to dig for it because it's right in front of us!
I TOLD you we would test 1.00 either today or tomorrow. Watch for a little profit taking possible, but definitely heading over 1.00 and staying there in the very near future!!!
I love this stock!!!
What a difference a day makes!
Right now we have strong catalysts in play for a move well over 1.00 pps.
1 - The deal with Cardinal where a number of juicy tidbits are coming into play that make this a much healthier and stronger company.
2 - The new patent!
3 - The 2 upcoming conferences in the next couple weeks!
4 - Possible upgrades forthcoming, but I will give you an upgrade right now - I am going with a strong buy!
Keep the faith, brother. It's fun making money with you and the other longs on here!
It's always nice to be on the train first!
And this is the money train. All aboard! Next stop - FORT KNOX!
Haha
Really looks like it is getting set up for another run....
High alert status! Ready for lift-off!!
Should test 1.00 either today or tomorrow. Hang in there guys - we haven't won yet but it's a good first step!!
Something very positive from that article I just posted:
7.3 million interest paid each year goes away.
When you clean up your balance sheet, good things will happen.
Well not too good of a day as we would have liked, but I think we got dragged to the lower portion of the channel along with the market. This happened a few days ago and we were dragged down to the .81 area but it looks like our channel will continue to be .82-.90 area until we can break out.
The good news is we do have a catalyst for breaking out far greater than that and we should hear on that very soon. Hopefully they are working with the bank to get that debt resolved ASAP because that is the millstone that has driven this company down.
I remain optimistic and hopeful that things will be resolved very soon. I hope that for myself and all other longs our patience will be rewarded in the near future and think of the lower channel as a good time to add to your position if you can.
There is a whole new breed of "investors" today that do not read the news - they merely go short of anything that has risen up, figuring the longs are in it for the quick buck and will vanish as soon as they take quick profits. When the buying dries up, it starts heading down.
This isn't investing, it's gambling. This is not an easy game and to be successful at it you have to read as much as you can and see where this is going. Does it have a reason more people will buy or sell it? You need to know more than the other guy, especially the other side.
This company isn't perfect or the stock would be trading at over 100.00 a share but I am convinced it is seriously undervalued and many people do not know all the details on how huge this deal is. It literally takes them out of the jaws of bankruptcy and puts them in a comfortable position where the debts are paid and they can move forward with a very good line of products.
I sincerely hope they can recoup the 4.1 million dollars the bank STOLE from them and get everything squared away. That 4.1 million should go to the principle of the loan and hopefully everything is resolved after this gets paid.
Good luck to all longs - hang in there and enjoy what should be a very nice gain for all of us!!
A nice 7 per cent gain today - pretty solid and sets us up nicely for tomorrow even with no news.
You don't want to be out of this when the news DOES hit and it could hit at any time, actually. After the bell, pre-market or during business hours. I read someone who wrote they were going to short this and I thought, "Yeah you go ahead and short this and see what happens when the news comes out!"
I am very confident this will continue upward. You need to be patient though - this is headed much higher!
BANG!!!! Just like that up to .888.
You can expect a lot more of that in the near future too!
Have a feeling it is going to run today. Get ready.
Yeah it's about all you can do, really. This may come back but it will probably take awhile.
Yeah, me too stockweiser. I have had a few of these over the years - I guess if you trade long enough EVERYONE does. Investing these days is like walking through a minefield. Hope you did not get burned too bad.
This is extremely bad news for GERN. This might be a 50 per cent correction the first hour alone.
I think there were some bargain basement shoppers - I almost got back in again at .15 for the bounce because I knew a lot of it was panic. There were a couple large blocks that went through! You can tell there is a lot of interest here and I don't think some will let it get too far down, but there is a top before things get settled and I am thinking .21 or so.
I have gone big on NAVB - I think that will pop big on news that should arrive any time so keep a close eye on that one!
BTW -- I think you get the best prices in premarket on SKLN - you can sell for the highest and pick up some cheaper as the day goes on. That worked for me! Good luck!
They HAVE to r/s and dilute to raise cash for these projects. This stock goes nowhere but down IMHO until they have this settled. You do not know what the r/s or dilution will be. It might be a 1-25 reverse split and then they dilute 100 million shares after that. If this happens the shareholders are screwed. Maybe this doesn't happen but maybe it does - you don't know.
That is why I said there is too much risk here to get invested immediately. See how it all plays out so you don't risk a huge loss on it.
After all this gets settled and we know a few more variables it may be a good stock going forward because I like the potential for future deals. But I am more than happy to let someone else pick up the tab and pick up the majority of the risk first.
Chairman Michael Goldberg - Navidea Biopharmaceuticals, Inc. - Conference Call 9/7/16
My opening statements - you have to think of this as a drug delivery system. Lymphoseek diagnostic is the first application -- so in the case of Lymphoseek, we are targeting lymph nodes, and we're targeting the receptor found on cells that are in the lymph nodes. And the differentiator of Lymphoseek versus the other agents which are not as good - Lymphoseek sticks there, so we can identify the first node, and we do with tremendous specificity, on the order of 10 to the minus 11 which is 1 in 100 billion molecules, so that's the beauty of the system. It's a capable drug delivery system that's been proven in humans, with the first application.
The next applications are to look at the same receptor but in different cells, instead of looking in lymph nodes, it's looking in cells that are behaving inappropriately in your joints, in the case of rheumatoid arthritis, or in your arteries. And the reason we been so successful in all of our animal studies on the therapeutic side is because it's the same mechanism based in different organs.
So in NASH we are looking at liver cells that eat too much fat. In atherosclerosis we're looking at macrophages in your arteries that also consume too much fat and cholesterol, and get turned on and become inflamed into Cardiovascular disease so we're attacking that. In Alzheimer's, it's because they are absorbing too much amyloid. You go down the list of all the diseases, it's really the same mechanism that we are using, and because of that, it's really just a delivery system. We're taking a proven delivery system based on Lymphoseek, we are taking proven drugs that we know work and based on animal studies with Lymphoseek and now applying it.
Other people have attacked these same cells, but not as specifically and not as safely as we think we can, even in humans. Like targeting approved drugs, through drugs like doxorubicin which causes apoptosis if delivered into high concentrations. It doesn't make a difference why the cells are behaving poorly, it doesn't make a difference why -- where or what organ they're in, it seems to work.
So for example, we have some amazing data in viruses where we can kill the virus, not by attacking or designing something specifically for a given virus, but because we can kill the cell that's hosting the virus. So again I don't see anything in the next quarter to slow us down because the system is proven, the agents we are delivering are proven and our platform is adaptable as needed.
So we can take anti-cancer agents that when given on their own can have toxicity, but also efficacy, and just target it better and therefore get more efficacy and less toxicity. We believe we have a greatly improved agent delivery system. That's the reason we are so excited by this deal. Again, we think that it's a win-win for us and Cardinal. Cardinal is going to get, we believe, a lifelong treatment and revenues from this product, because this will be very difficult product for anyone to compete with. But we get the capital and the resources we need from this deal, when cost of capital now is so high, that by selling future
revenues -- for nearer-term revenues, it's a real win-win for all of us.
And quite friendly for patients. It is a little disconcerting that we have the agent and a system that is so much better than any of the existing agents, and because of our lack of capital, we haven't been able to get it to become the standard of care quicker. And I believe that because of this deal,
Cardinal is going to get this into the hands of oncologists, surgeons, and many more patients are going to have a better diagnosis quicker, and not be subjected to another technology when really something as extraordinary as Lymphoseek is available, and I think this is good. Good for patients,
good for Cardinal, and great for Navidea.
No -- they will R/S ASAP.
There isn't going to be any avoiding it - you WILL be facing dilution and a reverse split on Sept. 15th - the only question is how much. It's too risky right now because you don't know all the cards and you could get burned. Why not wait until you know what you are dealing with first???
It DOES make sense, doesn't it?
There's no doubt this is a good stock to watch. They have an interesting future after things get settled down. I need to know what kind of r/s we are looking at and how much dilution. Too much dilution and your investment is worthless. You combine that with a r/s and that's a tough pill to swallow for anyone!
Good luck to the longs and I hope it goes well after the r/s.
Actually - this article was written on Friday and it didn't seem to help too much, but maybe the word did not get out yet. It certainly doesn't hurt us, though. This is the information that needs to get out to everyone and when everyone takes a look at it they will know what a tremendous opportunity we have here.
This deal needs to go through but there is every indication it will and very soon, too. When people become more informed as to the entire picture what we are dealing with there should be a solid bunch of buyers coming in. Keep reading as much as you can on the deal, what the CEO is saying and what other investors are saying. When this deal goes through, IMHO it will explode!
http://streetregister.com/2016/09/09/navidea-biopharmaceuticals-inc-nysemktnavb-pivots-poised-for-turnaround
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) Pivots, Poised For Turnaround
By Mike Robinson - September 9, 2016173
In Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)’s latest earnings call, analysts referenced the suffocating effect that an outstanding debt (and litigation related to said debt) was having on Navidea’s market capitalization and share price. The company is in the saddle for circa $50 million, owing to a credit facility extended to it by CRG, the global healthcare investment management firm, last year.
The debt and litigation has been, to put it lightly, a real thorn in Navidea’s side across the last twelve months, and as a result, despite what look to be some pretty solid underlying numbers, the company declined from just short of $2.50 a share this time last year, to $0.30 at August close – a close to 90% decline across the twelve-month period.
At the beginning of this week, however, the company announced what looks to be a final resolution on the matter – a resolution that should lift the above mentioned suffocating effect off the company and see it’s market capitalization start to recover.
Markets are already recognizing the potential impact of the resolution, and Navidea is up more than 165% on the week’s open.
So what’s happened?
Navidea has executed a non binding letter of intent (read: not closed yet, and very much dependent on due diligence) that will see it sell all rights and licensing to its lead product, Lymphoseek, to its lead distributor, Cardinal Health. The company will receive a license back to distribute the product outside of the US, and also develop products based on the technology that underpins Lymphoseek going forward.
In return for the rights, Cardinal Health is set to pay an $80 million upfront payment, as well as royalties and other payments based on sales volume, for a minimum of $6.7 million a year for the next three years, and with the total sale price not exceeding $310 million.
That’s the terms in a nutshell – what does it mean for Navidea?
The most important near term implication of this deal is that Navidea (subject to closing) can now pay off the $50 million debt it owes to CRG, in full, and free itself of the drag that the litigation has been putting on the company and its operations. This is not to be underestimated. The company’s CEO left earlier this year, primarily based on the impact of the litigation (whatever the media said) and reports of low morale, disgruntled staff and the reluctance of certain potential partners to strike deals with the company have hampered growth. The lifting of this situation is hugely important going forward.
The second implication is that Navidea now no longer has a revenue source. That’s not great, but according to a conference call held by management to discuss the deal, the company believes the potential future revenues from the development of its pipeline, specifically a rheumatoid arthritis treatment, outweigh the ROI on a marketing push for its Lymphoseek product.
This move can be interpreted as follows. The company is monetizing an asset to shore up its capital structure, and putting any remaining proceeds into its pipeline. We see this as a smart move. Why? Because any future growth potential was severely stunted by the company’s pre-agreement situation (of course, it’s very much still in this situation, but we are assuming the Cardinal Health deal will close out successfully).
Navidea is now an early stage junior biotech with a couple of promising candidates in its pipeline, no debt and a partnership that is set to bring in just shy of $7 million annually at the bottom end for at least three years. It should have cash on hand at close (and after paying off the debt and litigation costs) of between $25-30 million, and intends to counter CRG in the hope it can recoup some of its capital going forward.
That’s a pretty healthy position, and a complete turnaround for a company that, just last month, looked like a candidate for insolvency.
It’s not out of the woods yet, but as the deal closes and focus switches to the company’s pipeline, rather than its litigation, we expect Navidea to become a decent momentum play throughout the final quarter of this year.
Bullrider2 - If they can secure the deal and pay off the entire debt, they become an extremely attractive buyout candidate and it could go there. If it does - we win! However, I think they are in a great spot if the deal gets done just on their own and we win there, too. As the extremely positive article by Mike Robinson of the Street Register states on Friday, they have some very attractive drugs in their pipeline with no debt. He did not talk too much about their rights to retain Lymphoseek outside of North America and I think this is important. This could be a very strong revenue stream going forward and not to be taken lightly.
Of course this company and its shareholders want huge sales of Lymphoseek in North America even after the sale. We get 80 million dollars upfront. This means the 50 million dollar debt is paid in full and gives 30 million in the company coffers. Based on sales volume, we get a MINIMUM of 6.7 million a year but as much as an additional 230 million over three years if it really takes off. That would be 76.6 million a year on the high side.
If this deal goes through - we are in very very good shape and I think this stock flies. Good luck guys - I am very excited about this company and this stock. If it plays out like we hope this will be big money.
Amazed at this stock and I am watching it closely. The company spelled out exactly what it was going to do - that the conference call was going to call for the reverse split and dilution as well as give guidance on why they were doing this. When they announced it officially - the stock tanked. This means to me that a lot of shareholders didn't read this information and did not know. I think the smart money DID know this would happen and retail investors were clueless.
They need to r/s split and dilute to stay on the exchange - I get that. But to me once they take this short term pain and things get settled, this could be a very good stock going forward. They are setting up to get some nice cash flow with some very good contracts.
They most likely will get the R/S they need on the 15th at the meeting. If they don't they will be delisted and it's in nobody's best interest for that. My best hypothesis is this stock will meander where it is until investors get an idea of where this shakes out after the meeting on the 15th. Keep this on your watch list because it does have some very good potential very soon.
The MM's are banking on investors wanting to get the quick buck and bailing out if it doesn't move right away. That is one reason why so many people lose money on the stock market.
The Dow lost almost 500 points today - I watch about 50 stocks closely and most were down - probably about 7-8 out of 10. I think NAVB wanted to run and it got held down - plenty of downticks and it just stayed at .8101 X .8102 for a good part of the day and this was even with a very good positive article on it. I am not worried - once the news comes out I think we get this moving again but there is a lot of interest here and I think more people are seeing the potential we have going forward!
They wouldn't let it run today. They kept a lock down at .81 all day. My watch list is a red sea today - everything went down.
We will be back - just need to be a little patient but this will run and it will run fast as soon as things are sorted out.
very nice - I have a feeling we are going to get that news after hours this weekend. Just a hunch - there was someone on the yahoo msg board saying rumors are that the deal has been signed and it's just waiting for the press release.
I think either the MM's were either stealing shares or the shorts were terribly misguided here. There is zero reason to be selling here - tremendous buying opportunity right now. Hang on to your shares and buy as much as you can. The word is going to be out very soon and this will fly!
Just read it myself and I am extremely optimistic on this company going forward. The deal has to get done, but I think it should and that should really get this moving onward and upward!
Everything changed for the better with that 310 million dollar deal. The more I look at it, the more I like it - this could just launch at any time well over 1.00 per share. No way would I want to be short on this.
Man I hate reverse splits and dilution, but it must be done.
Needs a catalyst to break .23
And we just might get it at the all-important call tomorrow. We should also get some news on what the company is up to and what are some of the plans going forward.
I think there will be some people kicking themselves they sold today because I think we are going to get some good news. I strongly believe we will get that impetus that will take us above the resistance at .23 and beyond. Here is to a great day tomorrow for us longs and hopefully we can get some positive news we can build on for the future! Good luck!
Little bit of volume picking up - it's coming up on a few radar screens.
Agreed. When they correct the 8K and get that taken care of - it will pop. I am going with the rumour that things are getting resolved - we should find out very soon on this so watch out!